• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Fat Tail Daily

Investment Ideas From the Edge of the Bell Curve

  • Menu
    • Commodities
      • Resources and Mining
      • Copper
      • Gold
      • Iron Ore
      • Lithium
      • Silver
      • Graphite
      • Rare Earths
    • Technology
      • AI
      • Bitcoin
      • Cryptocurrency
      • Energy
      • Financial Technology
      • Bio Technology
    • Market Analysis
      • Latest ASX News
      • Dividend Shares
      • ETFs
      • Stocks and Bonds
    • Macro
      • Australian Economy
      • Central Banks
      • World Markets
    • Small Caps
    • More
      • Investment Guides
      • Premium Research
      • Editors
      • About
      • Contact Us
  • Latest
  • Fat Tail Series
  • About Us
Technology Bio Tech

Imugene Share Price Sink 7% after Flagging Three New Trials (ASX:IMU)

Like 0

By Kiryll Prakapenka, Wednesday, 01 September 2021

The Imugene [ASX:IMU] share price is floundering today on the back of an announcement regarding its HER-Vaxx immunotherapy in HER-2 positive gastric cancer trial.

The Imugene Ltd [ASX:IMU] share price is floundering today on the back of an announcement regarding its HER-Vaxx immunotherapy in HER-2 positive gastric cancer trial.

In early morning trade, IMU’s share price fell as low as 7%.

Since then, it has rebounded slightly and is now down 4% at time of writing.

ASX IMU - Imugene Share Price ChartSource: TradingView.com

Although the company’s announcement was largely positive, it’s possible investors could be seeing red flags.

Today, we’ll go through today’s announcement to get an outlook on Imugene shares.

What are these clinical trials all about?

Imugene is a unique biotech company that specialises in cancer immunotherapy.

Its lead product is HER-Vaxx, a cancer vaccine designed to target gastric cancer and breast cancer where the cancer is HER-2 positive.

Today’s release revealed the company’s phase 2 gastric cancer trial data.

A further three new trials were also announced.

But first, let’s take a look at the phase 2 trial.

This trial is designed to assess the efficacy, safety and immune response in metastatic gastric cancer overexpressing the HER-2 protein.

The main goal is overall survival (OS), with progression free survival (PFS) being a key secondary endpoint.

So far, 36 patients have been enrolled. Of those, 24 have achieved a PFS event in the study.

Although Imugene’s PFS hazard ratio was higher than the initial interim data from last year, it wasn’t too different from the landmark Genentech/Roche registrational ToGa study.

This study looked at similar phenomena.

In terms of getting an OS result, Imugene is still anticipating the events needed for an OS appraisal.

Based on the existing results, Imugene is now planning three new trials.

So why did the IMU share price drop?

It’s possible that the higher hazard ratio may have troubled some investors.

And if the company is investing in further trials, then high costs could also be a concern.

Clinical trials are lengthy, expensive exercises and new ones in the works could make a big dent in Imugene’s capital.

However, if the trials yield great results, then arguably the cost will be worth it.

Biotech is a fast-growing industry, and it has the power to change the face of healthcare as we know it.

But in terms of buying stocks, I’m not sure I’d jump headfirst into Imugene just yet.

Although the stock is up almost 300% in 2021, I’m still curious to see how the results from its future clinical trials pan out.

In any case, it’s an exciting play to consider.

That said, there are plenty of unique, high-potential opportunities to consider right now, particularly for those interested in getting into smaller ambitious companies.

These sorts of companies might be high-risk but if they achieve the level of success they’re shooting for, large gains could be for the taking.

Our leading small-cap stock market analyst Murray Dawes has found seven stocks on the ASX today he believes fit this description.

I recommend checking out Murray’s thoughts on these stocks.

There are some compelling ideas in there.

You can download Murray’s

 

Regards,

Kiryll Prakapenka,

For Money Morning

PS: Our publication Money Morning is a fantastic place to start on your investment journey. We talk about the big trends driving the most innovative stocks on the ASX. Learn all about it here

All advice is general advice and has not taken into account your personal circumstances.

Please seek independent financial advice regarding your own situation, or if in doubt about the suitability of an investment.

Kiryll Prakapenka

Kiryll’s Premium Subscriptions

Publication logo
Fat Tail Investment Research

Latest Articles

  • Ride Mining’s Profitable ‘Curve’ this Way
    By Callum Newman

    All week we’ve been on a mission. We’re unpicking the dynamics around gold, and gold stocks. Here’s a bit of advice on this opportunity,

  • Silver & Platinum Squeeze Higher
    By James Cooper

    Cycle Turns: Silver and Platinum on the move… Is it their industrial or precious metal angle that’s getting investors interested?

  • One forecast for gold: 10k per ounce!
    By Callum Newman

    Gold was long considered a “chaos” hedge, and protection against market sell offs and financial crisis. It can be that, for sure. But for now, the markets are bidding on both, because it’s inherently protection against currency depreciation. This is why bitcoin is surging toward new highs as well.

Primary Sidebar

Latest Articles

  • Ride Mining’s Profitable ‘Curve’ this Way
  • Silver & Platinum Squeeze Higher
  • One forecast for gold: 10k per ounce!
  • Three men, $20.8 million, and a $230 million rally… all in a day
  • Jamie Dimon’s warning means one thing only

Footer

Fat Tail Daily Logo
YouTube
Facebook
x (formally twitter)
LinkedIn

About

Investment ideas from the edge of the bell curve.

Go beyond conventional investing strategies with unique ideas and actionable opportunities. Our expert editors deliver conviction-led insights to guide your financial journey.

Quick Links

Subscribe

About

FAQ

Terms and Conditions

Financial Services Guide

Privacy Policy

Get in Touch

Contact Us

Email: support@fattail.com.au

Phone: 1300 667 481

All advice is general in nature and has not taken into account your personal circumstances. Please seek independent financial advice regarding your own situation, or if in doubt about the suitability of an investment.

The value of any investment and the income derived from it can go down as well as up. Never invest more than you can afford to lose and keep in mind the ultimate risk is that you can lose whatever you’ve invested. While useful for detecting patterns, the past is not a guide to future performance. Some figures contained in our reports are forecasts and may not be a reliable indicator of future results. Any actual or potential gains in these reports may not include taxes, brokerage commissions, or associated fees.

Fat Tail Logo

Fat Tail Daily is brought to you by the team at Fat Tail Investment Research

Copyright © 2025 Fat Tail Daily | ACN: 117 765 009 / ABN: 33 117 765 009 / ASFL: 323 988